Exelixis to Webcast Fireside Chats as Part of Investor Conferences in SeptemberBusiness Wire • 08/28/24
Investing in Exelixis (EXEL)? Don't Miss Assessing Its International Revenue TrendsZacks Investment Research • 08/12/24
Argonne's Autonomie Express tool simulates real-world vehicle traffic to predict large-scale energy impactBusiness Wire • 08/07/24
Exelixis (EXEL) Q2 Earnings Beat, Milestone Payments Fuel RevenuesZacks Investment Research • 08/07/24
Invenra Highlights Exelixis' Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid TumorsBusiness Wire • 08/07/24
Exelixis (EXEL) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/06/24
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateBusiness Wire • 08/06/24
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine TumorsBusiness Wire • 08/06/24
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024Business Wire • 07/23/24
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USABusiness Wire • 05/20/24